 |
They promise the moon—30%-plus annual returns. But they’ve underperformed the S&P 500 as a group, every year, since 2008…
Zero Hedge reports hedge funds suffered an abysmal month in June. Most came in nowhere near as “strong” as the S&P 500’s -2.10% returns for the month.
The worst in class: the “Tulip Trend Fund.” It posted returns of -14.61% in June. That brings its year-to-date (YTD) returns to -19.52%.
Keep in mind, a Tulip client would still pay according to hedge funds’ notorious “2-and-20” fee structure. (You pay 2% of your assets up front, and 20% of any gains to the fund manager.)
Regular Daily readers know you should sooner light your money on fire than turn it over to most hedge fund managers.
If you’re seeking the promise of “hedge fund-type” returns that can actually deliver, look to PBRG’s own Teeka Tiwari.
His Jump Point Trader (JPT) subscribers are crushing both the funds and the broad market. JPT’s mission is simple: Find companies with forward momentum, jump on them, and ride them for 100%-plus gains. It’s delivering: Since its inception, the service has beaten the S&P 500 by over 400%.
Here’s what Teeka’s research analyst, just sent me on JPT’s performance:
- Twelve out of 16 stocks are in the money (that’s a 75% win rate).
- The average gain for the 12 stocks is 23.4%.
- The portfolio’s total return is 16.1% since inception. This compares to the S&P 500 index, which is up 6.4% over the last 12 months… 1.98% YTD… and 3.13% since JPT’s inception.
- Of the four down positions, the average loss is 5.7%.
- Four of the 12 gainers have double-digit gains in eight months or less:
- JPT stock No. 1: + 64.66%
- JPT stock No. 2: + 25.56%
- JPT stock No. 3: + 21.48%
- JPT stock No. 4: + 19.54%
- One position just posted a triple-digit return in 60 days:
- Anacor Pharmaceuticals: +109.41%
Here’s what Teeka told his subscribers about triple-digit winner Anacor Pharmaceuticals in his May 13 buy alert message:
|
Anacor Pharmaceuticals, Inc. (Nasdaq: ANAC) is a Palo Alto, California-based biopharmaceutical company that sells novel, small-molecule therapeutics derived from its boron chemistry platform. Utilizing this platform, the company has advanced several proprietary boron-based products into clinical development. These products provide the company with significant market opportunities. In 2014, the company received U.S. Food and Drug Administration approval for Kerydin, the first boron-based antifungal drug approved for use in the United States. The stock rocketed by more than 16% in March after the company announced its revenue more than doubled Wall Street’s expectations. The stock has retraced some of those gains, giving us the Jump Point Trader opening we’ve been waiting for. |
Within 60 days of Teeka’s recommendation, the stock rocketed higher—after one of the company’s drugs completed Phase III clinical trials…
But that’s not all…
Teeka’s Jump Point Trader service also offers advanced traders an options trading component. This gives subscribers a little more “juice” to their trades. Here are the options numbers:
- 81.3% win rate.
- The average gain for each in-the-money option is 17.78%.
- The current portfolio return (open positions) is 13.51%.
- Six in-the-money options have double-digit gains in eight months or less:
- Option No. 1: +62.65%
- Option No. 2: +60.14%
- Option No. 3: +31.95%
- Option No. 4: +25.71%
- Option No. 5: +24.35%
- Option No. 6: +17.29%
- Anacor Pharmaceutical options have banked JPT subscribers 268% in 60 days.
Bottom line: The Jump Point Trader record speaks for itself. It demolishes the S&P 500. It crushes the hedge funds. And, unlike the funds, you don’t need to send Teeka 20% of these gains…